Published on FierceBiotech (http://www.fiercebiotech.com)

Merck KGaA - Biotech Market Share Report

By maureen
Created Sep 28 2008 - 8:06pm

Merck Market Share Report graphic featuring Merck, Erbitux and Rebif logosCompany: Merck KGaA
2007 Sales: $2.7 billion
Market share: 3.6%
CAGR: 17.9%

What they have: When Merck KGaA bought out Serono in 2006 it inherited Rebif, a top-selling multiple sclerosis drug. Merck is also one of three companies partnered on cancer drug Erbitux (along with ImClone and Bristo-Myers Squibb, which are not on this list). The drug is approved for head and neck and colorectal cancer.

What to look for: Merck KGaA has filed two additional indications for Erbitux and has a new formulation of Rebif in the works. The company is also cunducting late-stage testing for atacicept, an experimental rheumatoid arthritis treatment.

Previous: Abbott [1]Index [2]Next: Schering-Plough [3]
Source URL: http://www.fiercebiotech.com/special-reports/merck-kgaa

Links:
[1] http://www.fiercebiotech.com/special-reports/abbott-biotech-marketshare-report
[2] http://www.fiercebiotech.com/special-reports/biotech-marketshare-report
[3] http://www.fiercebiotech.com/special-reports/schering-plough-biotech-marketshare-report